0378: Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

0378

Click here to download this measure's specifications from the Cancer Project 2015-2016 project.

Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

STEWARD: American Society of Hematology

Measure Description:

Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

Numerator Statement:

Patients with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

Numerator Details:

${NumeratorDetails}

Denominator Statement:

All patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy

Denominator Details:

${DenominatorDetails}

Exclusions:

Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy

Exclusion Details:

${DenominatorExclusionDetails}

Risk Adjustment:

No risk adjustment or risk stratification

Classification:

Measure Type:

Process

Measure Format:

measure

Condition:

Cancer, Hematologic

Non-Condition Specific:

Safety: Medication, Safety

Care Setting:

Outpatient Services

National Quality Strategy Priorities:

Effective Communication and Care Coordination

Current Use:

Planned Use:

Data Source:

Registry Data

Level of Analysis:

Clinician: Group/Practice, Clinician: Individual

Target Population:

Elderly

Measure Selection Attributes (Learn more):

Measure Steward Contact Information:

For additional measure specification information, please contact the Measure Steward.

Measure Steward Organization:

American Society of Hematology

Primary Measure Steward Contact:

rplovnick@hematology.org

Measure Disclaimer:

Please see the copyright statement above in AD.6 for disclaimer information.

Measure Steward Copyright:

The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA) or the American Society of Hematology (ASH). Neither ASH, nor the AMA, nor the AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.

The AMA and ASH encourage use of the Measures by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

© 2015 American Medical Association and American Society of Hematology. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASH, the AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2004-2015 American Medical Association. LOINC® copyright 2004-2015 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2015 The International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2015 World Health Organization. All Rights Reserved.

Measure History: